nach oben

Erschienen in:

10.09.2021 | Pneumonie | CME

Therapie von Lungenfibrosen bei rheumatischen Systemerkrankungen (neue Therapien)

verfasst von: Katharina Buschulte, Anna-Maria Hoffmann-Vold, Rucsandra Dobrota, Philipp Höger, Andreas Krause, Prof. Dr. med. Michael Kreuter

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Eine interstitielle Lungenerkrankung stellt eine relevante Organmanifestation bei vielen rheumatischen Systemerkrankungen dar (CTD-ILD [„connective tissue disease-interstitial lung disease“]). In 10 % der Fälle geht eine Lungenfibrose einer zugrunde liegenden Systemerkrankung sogar voraus. Häufig sind CTD-ILDs mit einer schlechten Prognose assoziiert. Daher ist es wichtig, Patienten mit rheumatischen Systemerkrankungen früh und regelmäßig auf das Vorliegen einer ILD („interstitial lung disease“) hin zu untersuchen. Therapieentscheidungen, besonders bezogen auf die Einleitung einer spezifischen Therapie, sollten gemeinsam von Pneumologe und Rheumatologe getroffen werden. Die Therapien beruhen nur in wenigen Fällen auf randomisierten Studien, meist gehen diese auf Fallkontrollstudien zurück. Bei systemischer Sklerose-assoziierter ILD (SSc-ILD) ist neben einer immunsuppressiven Therapie nun auch eine antifibrotische Therapie mit Nintedanib zugelassen. Bei anderen CTD-ILDs ist eine antifibrotische Therapie je nach Grunderkrankung entsprechend einer progredient fibrosierenden ILD interdisziplinär zu diskutieren.

Kreuter M, Ladner UM, Heussel CP et al (2021) The diagnosis and treatment of pulmonary fibrosis. Dtsch Arztebl Int 5:118. https://doi.org/10.3238/arztebl.m2021.0018CrossRef

Wijsenbeek M, Cottin V (2020) Spectrum of fibrotic lung diseases. N Engl J Med 383:958–968CrossRefPubMed

Kreuter et al (2021) Pulmonale Manifestationen rheumatologischer Erkrankungen. In: Kreuter M, Costabel U, Kirsten D, Herth FJF (Hrsg) Seltene Lungenerkrankungen, 2. Aufl. Springer, Berlin Heidelberg

Hoffmann-Vold AM, Fretheim H, Halse AK et al (2019) Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am J Respir Crit Care Med 200(10):1258–1266. https://doi.org/10.1164/rccm.201903-0486OCCrossRefPubMed

Steen VD, Conte C, Owens GR, Medsger TA Jr (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37(9):1283–1289. https://doi.org/10.1002/art.1780370903CrossRefPubMed

EUSTAR collaborators, Hoffmann-Vold AM, Allanore Y, Distler O et al (2021) Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis 80(2):219–227. https://doi.org/10.1136/annrheumdis-2020-217455CrossRef

Oliveira RP, Ribeiro R, Melo L, Grima B, Oliveira S, Alves JD (2020) Connective tissue disease-associated interstitial lung disease. Pulmonology. https://doi.org/10.1016/j.pulmoe.2020.01.004CrossRefPubMedPubMedCentral

Distler O, Volkmann ER, Hoffmann-Vold AM, Maher TM (2019) Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. Expert Rev Clin Immunol 15(10):1009–1017. https://doi.org/10.1080/1744666X.2020.1668269CrossRefPubMed

Distler O, Assassi S, Maher TM et al (2020) Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J 55(5):1902026. https://doi.org/10.1183/13993003.02026-2019CrossRefPubMedPubMedCentral

10.

Fischer A, Strek ME, Cottin V et al (2019) Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: a multidisciplinary approach to address challenges and opportunities. Arthritis Rheumatol 71:182–195. https://doi.org/10.1002/art.40769CrossRefPubMed

11.

Medlin JL, Hansen KE, McCoy SS, Bartels CM (2018) Pulmonary manifestations in late versus early systemic lupus erythematosus: a systematic review and meta-analysis. Semin Arthritis Rheum 48(2):198–204. https://doi.org/10.1016/j.semarthrit.2018.01.010CrossRefPubMedPubMedCentral

12.

Barba T, Mainbourg S, Nasser M, Lega JC, Cottin V (2019) Lung diseases in inflammatory myopathies. Semin Respir Crit Care Med 40(2):255–270. https://doi.org/10.1055/s-0039-1685187CrossRefPubMed

13.

Li H, Xiong Z, Liu J, Li Y, Zhou B (2017) Manifestations of the connective tissue associated interstitial lung disease under high resolution computed tomography. Zhong Nan Da Xue Xue Bao Yi Xue Ban 42(8):934–939PubMed

14.

Duarte AC, Porter JC, Leandro MJ (2019) The lung in a cohort of rheumatoid arthritis patients-an overview of different types of involvement and treatment. Rheumatology 58:2031–2038. https://doi.org/10.1093/rheumatology/kez177CrossRefPubMed

15.

Suzuki A, Ohosone Y, Obana M, Mita S, Matsuoka Y, Irimajiri S, Fukuda J (1994) Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol 21:33–36PubMed

16.

Gabbay E, Tarala R, Will R et al (1997) Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 156:528–535CrossRefPubMed

17.

Ito Y, Arita M, Kumagai S et al (2019) Radiological fibrosis score is strongly associated with worse survival in rheumatoid arthritis-related interstitial lung disease. Mod Rheumatol 29:98–104. https://doi.org/10.1080/14397595.2018.1442170CrossRefPubMed

18.

EULAR Sjögren Syndrome Task Force, Ramos-Casals M, Brito-Zerón P, Vitali C et al (2017) Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology 54(12):2230–2238. https://doi.org/10.1093/rheumatology/kev200 (Erratum in: Rheumatology (Oxford). 56(7):1245.)CrossRef

19.

Ito I, Nagai S, Kitaichi M, Nicholson AG, Johkoh T, Noma S, Kim DS, Handa T, Izumi T, Mishima M (2005) Pulmonary manifestations of primary Sjogren’s syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 171(6):632–638. https://doi.org/10.1164/rccm.200403-417OCCrossRefPubMed

20.

Gao H, Zhang XW, He J, Zhang J, An Y, Sun Y, Jia RL, Li SG, Zhang LJ, Li ZG (2018) Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjögren syndrome patients: A case-control study. Medicine 97(24):e11003. https://doi.org/10.1097/MD.0000000000011003CrossRefPubMedPubMedCentral

21.

Roca F, Dominique S, Schmidt J et al (2017) Interstitial lung disease in primary Sjögren’s syndrome. Autoimmun Rev 16(1):48–54. https://doi.org/10.1016/j.autrev.2016.09.017CrossRefPubMed

22.

Panchabhai TS, Farver C, Highland KB (2016) Lymphocytic interstitial pneumonia. Clin Chest Med 37(3):463–474. https://doi.org/10.1016/j.ccm.2016.04.009CrossRefPubMed

23.

Tani C, Carli L, Vagnani S et al (2014) The diagnosis and classification of mixed connective tissue disease. J Autoimmun 48–49:46–49CrossRefPubMed

24.

Hyldgaard C, Hilberg O, Pedersen AB et al (2017) A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76:1700–1706CrossRefPubMed

25.

Moua T, Zamora Martinez AC, Baqir M, Vassallo R, Limper AH, Ryu JH (2014) Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia. Respir Res 15:154CrossRefPubMedPubMedCentral

26.

Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944CrossRefPubMedPubMedCentral

27.

Sato S, Masui K, Nishina N et al (2018) Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology 57(7):1212–1221. https://doi.org/10.1093/rheumatology/key060CrossRefPubMed

28.

Narula N, Narula T, Mira-Avendano I et al (2018) Interstitial lung disease in patients with mixed connective tissue disease: pilot study on predictors of lung involvement. Clin Exp Rheumatol 36(4):648–651PubMed

29.

Cao M, Sheng J, Cai H et al (2019) Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study. BMC Pulm Med 19(1):215. https://doi.org/10.1186/s12890-019-0960-1CrossRefPubMedPubMedCentral

30.

Kreuter M, Maher TM (2020) Treatment of acute exacerbation of idiopathic pulmonary fibrosis. A call to arms. Am J Respir Crit Care Med 201(9):1030–1032. https://doi.org/10.1164/rccm.202001-0057EDCrossRefPubMedPubMedCentral

31.

Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824. https://doi.org/10.1164/rccm.2009-040GLCrossRefPubMedPubMedCentral

32.

Kreuter M, Polke M, Bendstrup E et al (2020) Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. Eur Respir J 55(4):1901760. https://doi.org/10.1183/13993003.01760-2019CrossRefPubMed

33.

George PM, Spagnolo P, Kreuter M et al (2020) Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med 8(9):925–934. https://doi.org/10.1016/S2213-2600(20)30355-6CrossRefPubMed

34.

Fischer A, du Bois R (2012) Interstitial lung disease in connective tissue disorders. Lancet 380(9842):689–698CrossRefPubMed

35.

Hoffmann-Vold AM, Maher TM, Philpot EE et al (2020) The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol 2:e71–e83CrossRef

36.

American Thoracic Society Committee on BAL in Interstitial Lung Disease, Meyer KC, Raghu G, Wood B et al (2012) An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 185(9):1004–1014. https://doi.org/10.1164/rccm.201202-0320STCrossRef

37.

Wells AU (2010) The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease. Eur Respir Rev 19(117):237–241CrossRefPubMed

38.

Bouros D, Wells AU, Nicholson AG et al (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165(12):1581–1586CrossRefPubMed

39.

O’Dwyer DN, Ashley SL, Gurczynski SJ et al (2019) Lung microbiota contribute to pulmonary inflammation and disease progression in pulmonary fibrosis. Am J Respir Crit Care Med 199(9):1127–1138. https://doi.org/10.1164/rccm.201809-1650OCCrossRefPubMedPubMedCentral

40.

Raghu G, Flaherty KR, Lederer DJ et al (2019) Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. Lancet Respir Med 7(6):487–496. https://doi.org/10.1016/S2213-2600(19)30059-1CrossRefPubMed

41.

Kono M, Nakamura Y, Enomoto N et al (2014) Usual interstitial pneumonia preceding collagen vascular disease: a retrospective case control study of patients initially diagnosed with idiopathic pulmonary fibrosis. Plos One 9:e94775CrossRefPubMedPubMedCentral

42.

Fischer A, Antoniou KM, Brown KK et al (2015) An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 46:976–987CrossRefPubMed

43.

Ahmad K, Barba T, Gamondes D et al (2017) Interstitial pneumonia with autoimmune features: clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. Respir Med 123:56–62CrossRefPubMed

44.

Chartrand S, Swigris JJ, Stanchev L et al (2016) Clinical features and natural history of interstitial pneumonia with autoimmune features: a single center experience. Respir Med 119:150–154CrossRefPubMed

45.

Oldham JM, Adegunsoye A, Valenzi E et al (2016) Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J 47(6):1767–1775CrossRefPubMedPubMedCentral

46.

Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ (2014) Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol 66:803–812CrossRefPubMed

47.

Somogyi V, Krause A, Distler J, Kreuter M (2020) Interstitielle Lungenerkrankung bei Kollagenosen, Myositiden und rheumatoider Arthritis. In: Kompendium Rheumatologie, S 18–26

48.

Furer V, Rondaan C, Elkayam O et al (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79(1):39–52. https://doi.org/10.1136/annrheumdis-2019-215882CrossRefPubMed

49.

Visca D, Mori L, Tsipouri V et al (2018) Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med 6:759–770CrossRefPubMed

50.

Haidl P, Jany B, Geiseler J et al (2020) Leitlinie zur Langzeit-Sauerstofftherapie [Guideline for Long-Term Oxygen Therapy—S2k-Guideline Published by the German Respiratory Society]. Pneumologie 74(12):813–841. https://doi.org/10.1055/a-1252-1492CrossRefPubMed

51.

Dowman L, Hill CJ, Holland AE (2017) Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006322.pub3CrossRef

52.

Kreuter M, Bendstrup E, Russell AM et al (2017) Palliative care in interstitial lung disease: living well. Lancet Respir Med 5:968–980CrossRefPubMed

53.

Hoffmann-Vold AM, Allanore Y, Bendstrup E et al (2020) The need for a holistic approach for SSc-ILD—achievements and ambiguity in a devastating disease. Respir Res 21(1):197. https://doi.org/10.1186/s12931-020-01459-0CrossRefPubMedPubMedCentral

54.

Krause A, Kreuter M Lungenmanifestationen rheumatischer Erkrankungen. PneumoNews. https://doi.org/10.1007/s15033-020-1895-1/. Zugegriffen: 5. Jan. 2021

55.

Kouranos V, Miranda G, Corte TJ, Renzoni EA (2018) New treatment paradigms for connective tissue disease-associated interstitial lung disease. Curr Opin Pulm Med 24:453–460CrossRefPubMed

56.

Duarte AC, Cordeiro A, Fernandes BM et al (2019) Rituximab in connective tissue disease-associated interstitial lung disease. Clin Rheumatol 38:2001–2009CrossRefPubMed

57.

Fernández-Díaz C, Loricera J, Castañeda S (2018) Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients. Semin Arthritis Rheum 48:22–27CrossRefPubMed

58.

Khanna D, Lin CJF, Furst DE et al (2020) A randomised placebo-controlled phase 3 trial of tocilizumab in systemic sclerosis. Lancet Respir Med 8:963–974CrossRefPubMed

59.

Hornig J, Weinhage T, Schmidt LH et al (2018) Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment. Z Rheumatol 77:952–957. https://doi.org/10.1007/s00393-018-0565-8CrossRefPubMed

60.

Distler O, Highland KB, Gahlemann M et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 380:2518–2528. https://doi.org/10.1056/NEJMoa1903076CrossRefPubMed

61.

Flaherty KR, Wells AU, Cottin V et al (2019) Nintedanib in progressive Fibrosing interstitial lung diseases. N Engl J Med 381:1718–1727CrossRefPubMed

62.

Khanna D, Albera C, Fischer A et al (2016) An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol 43(9):1672–1679. https://doi.org/10.3899/jrheum.151322CrossRefPubMed

63.

Hsu VM, Denton CP, Domsic RT et al (2018) Pomalidomide in patients with interstitial lung disease due to systemic sclerosis: a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. J Rheumatol 45(3):405–410CrossRefPubMed

64.

Goodman SL, Picard M (2012) Integrins as therapeutic targets. Trends Pharmacol Sci 33(7):405–412CrossRefPubMed

65.

Mathai SC, Danoff SK (2016) Management of interstitial lung disease associated with connective tissue disease. BMJ 352:h6819CrossRefPubMedPubMedCentral

66.

Rojas-Serrano J, Herrera-Bringas D, Pérez-Román DI et al (2017) Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. Clin Rheumatol 36:1493–1500CrossRefPubMed

67.

Kiely P, Busby AD, Nikiphorou E et al (2019) Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. Bmj Open 9:1–12CrossRef

68.

Wijsenbeek M, Kreuter M, Olson A et al (2019) Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin 35:2015–2024CrossRefPubMed

69.

Tashkin DP, Roth MD, Clements PJ et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708–719CrossRefPubMedPubMedCentral

70.

Tashkin DP, Elashoff R, Clements PJ et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666CrossRefPubMed

71.

Hughes M, Denton CP, Khanna D (2021) Rituximab for the treatment of systemic sclerosis-interstitial lung disease. Rheumatology 60(2):489–491. https://doi.org/10.1093/rheumatology/keaa675CrossRefPubMed

72.

Hoffmann-Vold AM, Distler O, Murray B et al (2019) Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. RMD Open 5(1):e826. https://doi.org/10.1136/rmdopen-2018-000826CrossRefPubMedPubMedCentral

73.

Roofeh D, Lin CJF, Khanna D et al (2021) focuSSced investigators. Tocilizumab prevents progression of early systemic sclerosis associated interstitial lung disease. Arthritis Rheumatol. https://doi.org/10.1002/art.41668CrossRefPubMed

74.

Bauhammer J, Blank N, Fiehn C et al (2016) Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response. J Rheumatol 43(8):1566–1574. https://doi.org/10.3899/jrheum.150844CrossRefPubMed

75.

Barba T, Fort R, Cottin V et al (2019) Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev 18:113–122. https://doi.org/10.1016/j.autrev.2018.07.013CrossRefPubMed

76.

Chen Z, Wang X, Ye S (2019) Tofacitinib in amyopathic dermatomyositis—associated interstitial lung disease. N Engl J Med 381:291–293CrossRefPubMed

77.

Thompson GE, Specks U (2019) Update on the management of respiratory manifestations of the antineutrophil cytoplasmic antibodies-associated vasculitides. Clin Chest Med 40:573–582. https://doi.org/10.1016/j.ccm.2019.05.012CrossRefPubMed

Titel: Therapie von Lungenfibrosen bei rheumatischen Systemerkrankungen (neue Therapien)
verfasst von: Katharina Buschulte
Anna-Maria Hoffmann-Vold
Rucsandra Dobrota
Philipp Höger
Andreas Krause
Prof. Dr. med. Michael Kreuter
Publikationsdatum: 10.09.2021
Verlag: Springer Medizin
Schlagwörter: Pneumonie
Rheumatoide Arthritis
Systemische Sklerodermie
Nintedanib
Erschienen in: Zeitschrift für Rheumatologie / Ausgabe 8/2021
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI: https://doi.org/10.1007/s00393-021-01067-3

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2021

Neues zu seltenen rheumatologischen Erkrankungen in der Schwangerschaft

Fertilitätserhaltende Optionen vor gonadotoxischer antirheumatischer Therapie

Cushing-Syndrom mit konsekutiver tertiärer Nebennierenrindeninsuffizienz nach simultaner multipler intraartikulärer Lokaltherapie mit Glukokortikoiden

Aktuelles zur antirheumatischen Therapie bei Kinderwunsch, Schwangerschaft und Stillzeit

Erratum zu: Sport und Bewegungstherapie bei entzündlichen rheumatischen Erkrankungen

Relevantes zu Reproduktion und Rheuma